Post-earnings recap
Reported
Thu, Mar 1, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the lack of revenue details and no guidance led to a slight decline in the stock price. The market may be cautious as investors await more information on the company's future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +39.06% |
| Revenue | N/A | N/A | N/A |
Management remains positive about the future of their pipeline. However, they did not provide specific guidance for the upcoming quarters.
Management expressed confidence in ongoing projects despite not providing specific guidance.
They highlighted the importance of upcoming clinical trials.